RBC Capital analyst Matthew Hedberg lowered the firm’s price target on N-able (NABL) to $12 from $15 and keeps an Outperform rating on the ...
In a report released today, Lisa Walter from RBC Capital maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), with a ...
Cranswick said it had a record Christmas trading period, buoyed by strong demand for its premium value-added products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback